TNFSF10 and hepatocellular carcinoma: Taken together, these in vivo results imply that the identified lead compounds (TRT-0029 and TRT-0173) exhibit HCC anti-tumor efficacy in cooperation with TRAIL based on their bioavailability in tumor tissues.